DermTech, Inc. affirms revenue guidance for the full-year 2022. The company affirmed its full-year 2022 outlook for assay revenue between $22 million and $26 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.42 USD | +18.31% | -26.33% | -76.00% |
14/05 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
22/04 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-76.00% | 1.45Cr | |
-6.16% | 1.21TCr | |
-3.26% | 820.93Cr | |
+6.61% | 573.9Cr | |
+31.20% | 563.82Cr | |
-9.05% | 415.71Cr | |
-56.99% | 288.14Cr | |
+11.87% | 268.69Cr | |
-5.34% | 232.56Cr | |
+25.34% | 217.13Cr |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022